Bezlotoxumab: First Global Approval.

Article Details

Citation
Copy to clipboard

Markham A

Bezlotoxumab: First Global Approval.

Drugs. 2016 Dec;76(18):1793-1798. doi: 10.1007/s40265-016-0673-1.

PubMed ID
27905086 [ View in PubMed
]
Abstract

Bezlotoxumab (Zinplava) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co. In October 2016 it was approved in the USA for reducing the recurrence of C. difficile infection. This article summarizes the milestones in the development of bezlotoxumab leading to this first approval for use in patients receiving antibacterial drug treatment for C. difficile infection who are at high risk for recurrence of C. difficile infection.

DrugBank Data that Cites this Article

Drugs